Research programme: anti-cancer monolconal antibodies - Abeome Corporation

Drug Profile

Research programme: anti-cancer monolconal antibodies - Abeome Corporation

Alternative Names: ABM 101; ABM 193; ABM101 - Abeome; Anti-OX40 mAb; Anti-PD-L1 mAb; Anti-T-cell antibodies

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Abeome Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists; Programmed cell death 1 ligand 2 protein inhibitors; T-cell receptor antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Apr 2017 Research programme: anti-cancer monolconal antibodies - Abeome Corporation is available for licensing as of 24 Apr 2017. http://abeomecorp.com (Abeome pipeline, April 2017)
  • 24 Apr 2017 Pharmacodynamics data from preclinical trials in Cancer released by Abeome Corporation
  • 01 Apr 2017 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top